Dr. Ana Pilar Ramos Ttito

NEURÓLOGA

EPILEPTÓLOGA

CONÓCEME

Soy médico especialista en neurología egresada de la Universidad Peruana Cayetano Heredia , y subespecialista en el manejo avanzado de epilepsia por la Universidad de Western Ontario en Canadá , certificada por la Sociedad Clínica de Neurofisiología Canadiense.
Me desempeño como médico neurólogo en el Hospital Nacional Cayetano Heredia y la Clínica San Felipe, y docente por la Universidad Peruana Cayetano Heredia. Así mismo, soy investigadora, y miembro asociado del Instituto de Medicina Tropical Alexander von Humboldt de la Universidad Peruana Cayetano Heredia. Mis líneas de investigación e interés son principalmente las relacionadas al manejo de las enfermedades Neuroinfecciosas , Neuroinmunológicas y Epilepsia.

Dra. Ana Pilar Ramos Ttito

CMP 47269
RNE 035393 RNE 035393

CSCN (Canadian Society Clinical Neurophysiologists) 6526

CONFERENCE

Stroke in the setting of COVID-19 infection among patients attending a public hospital in Lima, Peru

Best Video Case Presentation at the International Parkinson and Movement Disorder Society´s: Movements Disorders in NMDA-AMPA autoimmune encephalitis., 2018

Takotsubo cardiomyopathy as a sequel of severe dysautonomia from guillain-barre syndrome.
Chronic inflammatory demyelinating polyneuropathy associated with HIV and neurosyphilis coinfection.

PUBLICACIONES CIENTÍFICAS

2023: Ana P Ramos, Jorge G Burneo. Seizures and epilepsy associated with central nervous system tuberculosis. Seizure. 2023 Apr 107:60-66. PMID: 36963243.
2021: Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Castañeda CC, Dioses JA, Tipismana MA, Abanto JT, Llanos A, Gourlay D, Grogl M, Ramos M, Rojas JD, Meza R, Puiu D, Sherman RM, Salzberg SL, Simner PJ, Willison HJ, Jacobs BC, Cornblath DR, Umeres HF, Pardo CA. Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 5;8(2):e952. PMID: 33547152.
2020: Martinez-Hernandez E, Guasp M, García-Serra A, Maudes E, Ariño H, Sepulveda M, Armangué T, Ramos AP, Ben-Hur T, Iizuka T, Saiz A, Graus F, Dalmau J. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology. 2020 Jun 2;94(22):e2302-e2310. PMID: 32161029.
2023: Castro MDM, Rode J, Machado PRL, Llanos-Cuentas A, Hueb M, Cota G, Rojas IV, Orobio Y, Oviedo Sarmiento O, Rojas E, Quintero J, Pimentel MIF, Soto J, Suprien C, Alvarez F, Ramos AP, Arantes RBDS, da Silva RE, Arenas CM, Vélez ID, Lyra MR, Saravia NG, Arana B, Alexander N. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLoS Negl Trop Dis. 2023 Jan 23;17(1):e0011029. doi: 10.1371/journal.pntd.0011029. PMID: 36689465; PMCID: PMC9894540.
2022: López L, Valencia B, Alvarez F, Ramos AP, Llanos-Cuentas A, Echevarria J, Vélez I, Boni M, Rode J, Quintero J, Jiménez A, Tabares Y, Méndez C, Arana B. A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. PLoS Negl Trop Dis. 2022 Mar 7;16(3):e0010238. doi: 10.1371/journal.pntd.0010238. PMID: 35255096; PMCID: PMC9560618.
2022: Valencia BM, Lau R, Kariyawasam R, Jara M, Ramos AP, Chantry M, Lana JT, Boggild AK, Llanos-Cuentas A. Leishmania RNA virus-1 is similarly detected among metastatic and non-metastatic phenotypes in a prospective cohort of American Tegumentary Leishmaniasis. PLoS Negl Trop Dis. 2022 Jan 28;16(1):e0010162. doi: 10.1371/journal.pntd.0010162. PMID: 35089930; PMCID: PMC8827429.
2021: Serrano-Coll H, Cardona-Castro N, Ramos AP, Llanos-Cuentas A. Innate immune response: ally or enemy in cutaneous leishmaniasis? Pathog Dis. 2021 Jun 8;79(5):ftab028. doi: 10.1093/femspd/ftab028. PMID: 34037758.
2020: Pineda-Reyes J, Marín R, Tinageros-Zevallos A, Ramos AP, Alvarez F, Llanos-Cuentas A. Manipulation of cutaneous leishmaniasis lesions: case series in a peruvian hospital. Rev Peru Med Exp Salud Publica. 2020 Apr-Jun;37(2):265-269. Spanish, English. doi: 10.17843/rpmesp.2020.372.4799. Epub 2020 Aug 28. PMID: 32876215.
2011: Boggild AK, Valencia BM, Veland N, Pilar Ramos A, Calderon F, Arevalo J, Low DE, Llanos-Cuentas A. Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology. PLoS One. 2011;6(10):e26395. PMID: 22046280.
2011: Veland N, Espinosa D, Valencia BM, Ramos AP, Calderon F, Arevalo J, Low DE, Llanos-Cuentas A, Boggild AK. Polymerase Chain Reaction Detection of Leishmania kDNA from the Urine of Peruvian Patients with Cutaneous and Mucocutaneous Leishmaniasis. Am. J. Trop. Med. Hyg., 84(4), 2011, pp. 556–561. PMID: 21460009.
2011: Boggild AK, Pilar Ramos A, Veland N, Valencia BM, Calderon F, Arevalo J, Low DE, Llanos-Cuentas A. Diagnostic Performance of Filter Paper Lesion Impression PCR in both Secondarily Infected Ulcers and Non-ulcerative Lesions of Cutaneous Leishmaniasis. J Clin Microbiol 2011 Mar;49(3):1097-100. PMID: 21177908.
2010: Boggild AK, Ramos AP, Espinosa D, Valencia BM, Veland N, Miranda-Verastegui C, Arevalo J, Low DE, Llanos-Cuentas A. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg. 2010 Aug;83(2):345-50. PMID: 20682880.
2010: Boggild AK, Valencia BM, Espinosa D, Veland N, Ramos AP, Arevalo J, Llanos-Cuentas A, Low DE. Detection and species identification of Leishmania DNA from filter paper lesion impressions for patients with American cutaneous leishmaniasis. Clin Infect Dis. 2010 Jan 1;50(1):e1-6. PMID: 19947858